In this episode of Crux of Neuro, Liz is joined by Fred Walke, Founder and CEO of Wave Neuro, to explore why transcranial magnetic stimulation (TMS) has traditionally relied on standardised treatment protocols, and whether a more personalised approach could transform the future of mental healthcare. From becoming a CEO at just 29 and helping transform the dental industry to building a company focused on precision neuromodulation, Fred shares the unconventional journey that brought him into neuroscience. What began as scepticism towards a complex technology became a deeply personal mission after witnessing his daughter’s struggles with mental health and the changes he observed following an individualised course of treatment. The conversation examines how Wave Neuro uses electroencephalography (EEG) data to inform personalised TMS protocols, why Fred believes objective brain measurements should play a greater role in mental healthcare, and what it will take to make non-invasive treatment more accessible to patients worldwide.